Pfizer bets up to $10.5B in 12-candidate cancer collab with China’s Innovent
BioSpace
Pfizer continues its dealmaking spree by striking a back-heavy partnership with China's Innovent Biologics to assemble a pipeline of antibody-based therapies for cancer.
pharminent
May 29, 2026 (Last updated: May 29, 2026)
BioSpace
Pfizer continues its dealmaking spree by striking a back-heavy partnership with China’s Innovent Biologics to assemble a pipeline of antibody-based therapies for cancer.